These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18695371)

  • 1. Activated protein C in sepsis: a critical review.
    Levi M
    Curr Opin Hematol; 2008 Sep; 15(5):481-6. PubMed ID: 18695371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human activated protein C (Xigris).
    Levi M; De Jonge E; van der Poll T
    Int J Clin Pract; 2002 Sep; 56(7):542-5. PubMed ID: 12296618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Bartelink AK
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):352-4. PubMed ID: 16523795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C for the treatment of severe sepsis.
    Houston G; Cuthbertson BH
    Clin Microbiol Infect; 2009 Apr; 15(4):319-24. PubMed ID: 19416303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies.
    Woodward B; Cartwright M
    J Crit Care; 2009 Dec; 24(4):595-602. PubMed ID: 19327331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
    Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV
    Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemorrhagic risk of drotrecogin alfa (activated) in severe sepsis].
    Perrotin D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():16-9. PubMed ID: 15359934
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of activated protein C in the pathophysiology of severe sepsis.
    Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
    Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Should patients with severe sepsis be treated with activated protein C?].
    Laake JH; Bergmann JB; Riddervold F; Bjørneklett A; Aukrust P; Frøland SS
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):782-4. PubMed ID: 15039808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Activated protein C--recent addition to therapy of sepsis].
    Gårdlund B; Sjölin J
    Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 17. Activated protein C (Xigris) for severe sepsis.
    Med Lett Drugs Ther; 2002 Feb; 44(1124):17-8. PubMed ID: 11856952
    [No Abstract]   [Full Text] [Related]  

  • 18. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 20. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.